Advancing the Cardiovascular Care of the Oncology Patient Virtual On Demand

Advancing the Cardiovascular Care of the Oncology Patient

The ACC will be performing a monthly system maintenance from Saturday, April 24th at 10 p.m. ET until Sunday, April 25th at 6 a.m. ET. During this time, Advancing the Cardiovascular Care of the Oncology Patient Virtual will be unavailable. We thank you for your patience as we continue to improve our systems to serve you better.

Access until April 25, 2021

Registration closed on April 12, 2021

Listen to Course Directors Ana Barac, MD, PhD, FACC and Bonnie Ky, MD, MSCE, FACC, and other leaders in the field, as they provide you with the tools needed to improve patient care in your everyday practice!

Purchase Advancing the Cardiovascular Care of the Oncology Patient Virtual On Demand today.

Gain access to over 14 hours of education:

  • Pharmacology essentials for Cardio-Oncology
  • Cardio-Oncology best practices
  • Scientific and Professional Development posters from researchers and Cardio-Oncology programs
  • Case presentations from your Cardio-Oncology Community peers
  • Access On Demand sessions until April 25, 2021!

Statement of Educational Need/Overview
Cardiovascular disease is the second leading cause of morbidity and mortality in cancer survivors. Since an estimated 14.5 million cancer patients and survivors have significant cardiovascular risk factors, it is critical for cardiologists, oncologists, and the entire multi-professional care team to stay on the leading edge of this rapidly evolving field!


Educational Program Goal
The overall goal of this course is to provide clinically relevant, state-of-the-art, best practice strategies for the multi-professional care team in the assessment, diagnosis, and management of cardiovascular concerns for patients with cancer and/or those requiring survivorship care.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the different types and mechanisms of action of conventional and modern cancer therapies, their associated cardiotoxicities, and the risks of developing cardiovascular risk factors and cardiovascular disease.
  • Describe the rapidly evolving advances in cancer immunotherapy and the associated cardiotoxicity.
  • Define cardiovascular complications in cancer patients that are specific to coronary disease, vascular disease, and bleeding/thrombosis.
  • Recognize guideline recommendations regarding risk stratification, monitoring, and management strategies to mitigate cardiovascular risk in the oncology patient.
  • Apply evidence-based strategies for short- and long-term surveillance and management of cardiotoxicities in patients with active cancer and survivors who have been treated with high cardiovascular risk systemic therapies including, but not limited to, anthracyclines, stem cell transplantation, and radiation therapy.
  • Recognize the appropriate diagnostic biomarker and imaging modalities to diagnose and predict cardiotoxicity.
  • Define the role of preventive and therapeutic non-pharmacologic interventions in the management of cardiotoxicity.
  • Discuss the pathologic basis of amyloidosis including diagnosis and treatment strategies.
  • Establish interprofessional Cardio-Oncology care teams and a framework to improve overall cardiovascular care of cancer patients and survivors.

Target Audience
The target audience is cardiovascular specialists, oncologists, internists, and all members of the multi-professional care team (including advanced practice providers, pharmacists, and nurses), who are providing clinical care to the growing population of cancer patients and survivors with cardiovascular concerns.

Course Directors

Ana Barac, MD, PhD, FACC
Medstar Washington Hospital Center

Bonnie Ky, MD, MSCE, FACC
University of Pennsylvania School of Medicine

Planning Committee

Rachel Barish, MSN, ANP-BC, AACC
Medstar Georgetown Physicians Group

Christine Cambareri, PharmD, BCPS, BCOP
Hospital of the University of Pennsylvania

Mitchell Hughes, PharmD, BCPS, BCOP
Hospital of the University of Pennsylvania

Kevin Oeffinger, MD
Duke University

Eric Yang, MD, FACC, FASE
UCLA Cardiovascular Center, University of California at Los Angeles

Social Media Moderator

Sherry-Ann Brown, MD, PhD, FACC, FAHA
Medical College of Wisconsin

Faculty

Saro Armenian, DO, MPH
City of Hope Comprehensive Cancer Center

Anne Blaes, MD
University of Minnesota

Michael Fradley, MD
University of Pennsylvania

Ludhmila Abrahao Hajjar, MD
Universidade de São Paulo

David Hodgson MD, MPH, FRCPC
University of Toronto

Alok A. Khorana, MD
Cleveland Clinic

Daniel Lenihan, MD
Washington University in St. Louis

Michaela Liedtke, MD
Stanford University School of Medicine

Teresa López-Fernández, MD
La Paz University Hospital

Charlotte Manisty, MD, PhD, FRCP, FESC
University College London and Barts Heart Centre

Vivek Narayan, MD, MS
University of Pennsylvania, Abramson Cancer Center

Tomas G. Neilan, MD, MPH, FACC
Massachusetts General Hospital

Anju Nohria, MD, MSc
Brigham and Women's Hospital/Dana Farber Cancer Institute

Dinesh Thavendiranathan, MD, MSc, FASE
University of Toronto

Ronald Witteles, MD, FACC
Stanford University School of Medicine

Faculty are subject to change without notice.

Disclosure/Conflict of Interest Statement

As a provider jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), the American College of Cardiology Foundation (ACCF) must ensure balance, independence, objectivity and scientific rigor in all of their directly provided or jointly provided/co-provided educational activities. Planners, presenters, and other contributors, in a position to control the content are required to disclose to the audience all relevant financial relationships he/she and/or his/her spouse or domestic partner may have, occurring within the past 12 months, with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the contributor should disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCF is committed to providing its learners with high-quality activities and materials that promote improvements and quality in health care and not a specific proprietary business or commercial interest. The intent of this disclosure is not to prevent participation in educational activities by persons with a financial or other relationship, but rather to provide learners with information on which they can make their own determination whether financial interests or relationships may influence the education activity.

ACCF assesses conflicts of interest (COI) with its faculty, planners, managers, staff and other individuals who are in a position to control the content of certified activities. All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors, ACCF education staff, and members of the Accreditation Compliance Workgroup (ACWG) through a process that includes appropriate peer review for fair balance, scientific objectivity and validity, and patient care and safety recommendations.

Please note ACCF staff and the ACWG members involved with this activity have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, the American College of Cardiology Foundation (ACCF) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement

Physicians
The ACCF designates this other activity (live virtual and on demand) for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
The ACCF designates this educational activity for a maximum of 14 continuing nursing education contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants
Other Activity (live virtual and on demand)
The American College of Cardiology Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 14 AAPA Category 1 CME credits.

Approval is valid until April 25, 2021. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists
ACCF designates this continuing education activity for 10.5 contact hours (1.05 CEUs) of the Accreditation Council for Pharmacy Education.

Interprofessional
This activity was planned by and for the healthcare team, and learners will receive 6.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

While offering credits noted above, the course is not intended to provide extensive training or certification in this field.

Clinical Topics: Cardio-Oncology

Keywords: Cardiotoxicity